Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intesti13 + Sb-1
- Development stage
- Preclinical
- Lead developer
- George Eliava Institute of Bacteriophage, Microbiology and Virology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Intesti13 + Sb-1 is an experimental two-phage cocktail consisting of the lytic bacteriophages Intesti13 and Sb-1, both belonging to the *Kayvirus* genus of the *Herelleviridae* family. Developed by the George Eliava Institute of Bacteriophages, Microbiology and Virology, this cocktail is designed to target *Staphylococcus aureus*, including methicillin-resistant *Staphylococcus aureus* (MRSA) and daptomycin-nonsusceptible (DNS) MRSA strains. The phages act by binding to specific bacterial cell surface receptors, injecting their genomic DNA, and undergoing a lytic cycle that results in bacterial cell lysis. This cocktail has been investigated in combination with antibiotics like daptomycin and ceftaroline, demonstrating synergistic bactericidal activity and biofilm eradication in preclinical models of deep-seated infections such as infective endocarditis and medical device-related infections.
- Other names
- Intesti13 + Sb1Intesti13 and Sb-1Intesti-13 and Sb-1Intesti 13 and Sb-1Intesti13 and Sb1Intesti-13 and Sb1Intesti 13 and Sb1
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on Intesti13 + Sb-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intesti13 + Sb-1.